<?xml version="1.0" encoding="UTF-8"?>
<p id="p0275">Camostat mesylate is considered the standard inhibitor of TMPRSS2 and it has been demonstrated that it is able to inhibit the proteolytic activity of TMPRSS2 even at the lowest concentration of 100Â nM, thus reducing the probability of SARS-CoV-2 penetration in cell experiments 
 <italic>in vitro</italic>
 <xref rid="b0420" ref-type="bibr">[84]</xref>, 
 <xref rid="b0095" ref-type="bibr">[19]</xref>, 
 <xref rid="b0455" ref-type="bibr">[91]</xref> (see 
 <xref rid="f0025" ref-type="fig">Fig. 5</xref>C). Similarly, the Nafamostat, a structural analog of Camostat, blocks SARS-CoV-2 infection of human lung cells with 15-fold higher efficiency than Camostat mesylate; this makes it a good compound to enter clinical trials for COVID-19 treatment 
 <xref rid="b0100" ref-type="bibr">[20]</xref>.
</p>
